Neurophet, a company specializing in AI solutions for brain disorder diagnosis and treatment, said Tuesday that it will participate in the 64th Annual Meeting of the American Society of Neuroradiology (ASNR 2026), which will be held in Austin from Sunday to next Wednesday (local time).
At the conference, Neurophet will showcase Neurophet AQUA AD Plus, a comprehensive brain imaging analysis solution designed to support Alzheimer’s disease treatment decisions.
Neurophet will participate in the 64th Annual Meeting of the American Society of Neuroradiology (ASNR 2026) in Austin from Sunday to next Wednesday (local time). (Courtesy of Neurophet)
The software quantitatively analyzes MRI (magnetic resonance imaging) and PET (positron emission tomography) scans to assist clinicians throughout the treatment cycle -- from assessing patient eligibility before prescription, to monitoring adverse effects during treatment, and evaluating therapeutic outcomes after administration.
Through its exhibition booth, the company will also introduce Neurophet AQUA, a neurodegenerative brain imaging analysis software, and Neurophet SCALE PET, a PET image quantification solution. In addition, Josh Cohen, head of Neurophet Americas, will deliver a presentation during the conference under the theme “Therapeutic Impact in Alzheimer’s Disease.”
“We are seeing growing demand from both domestic and international medical institutions for Neurophet AQUA AD Plus in the field of imaging analysis related to Alzheimer’s disease treatment prescriptions,” said Been Jun-kil, co-CEO of Neurophet. “Participation in ASNR 2026 will serve as an opportunity to expand partnerships with global healthcare companies and further broaden product adoption among local medical institutions.”
ASNR 2026 is an international academic conference focused on imaging technologies and clinical research related to central nervous system disorders, including diseases of the brain and spinal cord. The event brings together physicians and researchers from around the world to exchange the latest scientific and clinical insights.
Lee Han-soo
댓글
0